Henoch-Schönlein Purpura (Adult)

Henoch-Schönlein Purpura (Adult): A Comprehensive Clinical Guide

Henoch-Schönlein Purpura (HSP), now more formally recognized as Immunoglobulin A Vasculitis (IgAV), represents the most common form of systemic small-vessel vasculitis. While historically categorized as a pediatric condition, adult-onset IgA vasculitis presents a distinct clinical profile, often characterized by more severe systemic involvement, higher rates of renal complications, and a more protracted clinical course. As an expert clinical specialist, this guide delineates the complex pathophysiology, diagnostic rigor, and management paradigms required for the adult patient.

1. Comprehensive Introduction & Overview

Henoch-Schönlein Purpura (HSP) is a small-vessel vasculitis characterized by the deposition of immunoglobulin A (IgA) immune complexes within the vessel walls. Unlike the self-limiting nature often observed in pediatric populations, adult HSP represents a more significant diagnostic and therapeutic challenge.

Clinical Definition

IgA vasculitis is defined by the presence of palpable purpura (typically in the lower extremities) in the absence of thrombocytopenia or coagulopathy, accompanied by at least one of the following:
* Arthritis or arthralgia.
* Abdominal pain or gastrointestinal involvement.
* Renal involvement (hematuria/proteinuria).
* Histopathologic evidence of IgA deposition.

Epidemiology in Adults

While the incidence in children is approximately 10–20 per 100,000, adult incidence is significantly lower (estimated at 0.1–1.3 per 100,000). However, the mortality and morbidity rates are higher in adults, primarily due to the increased frequency and severity of IgA nephropathy (IgAN).

2. Deep-Dive: Mechanisms and Pathophysiology

The pathophysiology of HSP in adults is rooted in an aberrant immune response, specifically involving the galactose-deficient IgA1 (Gd-IgA1) molecule.

The Multi-Hit Hypothesis

The development of IgAV follows a recognized "multi-hit" sequence:
1. Hit 1: Genetic predisposition leading to the production of abnormal Gd-IgA1.
2. Hit 2: Production of autoantibodies (IgG or IgA) directed against the exposed hinge region glycans of Gd-IgA1.
3. Hit 3: Formation of circulating immune complexes (CICs) composed of Gd-IgA1 and anti-Gd-IgA1 antibodies.
4. Hit 4: Deposition of these complexes in the small vessels of the skin, joints, gastrointestinal tract, and renal glomeruli, triggering the alternative complement pathway and leukocyte recruitment.

Histopathology

Microscopic examination of affected tissue (skin or renal biopsy) typically reveals:
* Leukocytoclastic Vasculitis: Characterized by neutrophilic infiltration, nuclear fragmentation (leukocytoclasis), and fibrinoid necrosis of vessel walls.
* Immunofluorescence: The diagnostic hallmark is the granular deposition of IgA (and often C3) in the mesangium of the glomeruli or the walls of dermal capillaries.

3. Clinical Indications & Standard Presentation

Adult patients rarely present with the "classic" triad observed in children. The clinical presentation is often more heterogeneous and insidious.

Diagnostic Criteria (EULAR/PRINTO/PRES)

To standardize diagnosis, clinicians utilize the following criteria:
* Mandatory Criterion: Palpable purpura (non-thrombocytopenic).
* Requirement of one or more of the following:
* Diffuse abdominal pain: Often colicky; may lead to intussusception or bowel perforation.
* Any biopsy showing IgA deposition: Skin or renal.
* Arthritis or Arthralgia: Usually migratory, affecting large joints (knees, ankles).
* Renal involvement: Hematuria (>5 RBC/hpf) or proteinuria (>0.3g/24hr).

Clinical Grading Table

4. Differential Diagnosis

Distinguishing IgAV from other vasculitides and systemic conditions is paramount to prevent inappropriate treatment.

• Microscopic Polyangiitis (MPA): Usually ANCA-positive; lacks the IgA deposition signature.
• Cryoglobulinemic Vasculitis: Associated with Hepatitis C; look for low C4 levels and positive cryoglobulins.
• Systemic Lupus Erythematosus (SLE): Often presents with ANA positivity and multi-organ involvement.
• Hypersensitivity Vasculitis: Often drug-induced; usually lacks the intense IgA deposition seen in HSP.
• Henoch-Schönlein vs. IgA Nephropathy: Clinically, they are considered two ends of the same spectrum. If the patient has no systemic symptoms (skin/joint/GI) but has IgA deposition in the kidney, it is classified as IgA Nephropathy rather than HSP.

5. Key Diagnostic Tests

A systematic approach is required for every suspected adult case.

Laboratory Workup

• Complete Blood Count (CBC): To rule out thrombocytopenia (essential to exclude ITP).
• Urinalysis/Urine Protein-Creatinine Ratio: To identify subclinical renal involvement.
• Serum Creatinine/BUN: To assess baseline renal function.
• Coagulation Profile (PT/PTT): To rule out coagulopathy.
• Inflammatory Markers: ESR and CRP are typically elevated.
• IgA Levels: Often elevated, though not specific.
• ANCA Testing: To rule out other forms of systemic vasculitis.

Imaging and Biopsy

• Skin Biopsy: Punch biopsy of a fresh lesion (within 24-48 hours) for H&E and direct immunofluorescence.
• Renal Biopsy: Indicated in adults if there is significant proteinuria, hematuria, or declining renal function.
• Abdominal Ultrasound/CT: Indicated if severe abdominal pain suggests intussusception, obstruction, or perforation.

6. Risks, Side Effects, and Contraindications

Managing adult HSP requires a delicate balance between immune suppression and the risk of infection.

• Corticosteroids: The cornerstone of treatment for moderate-to-severe disease. Side effects include hyperglycemia, hypertension, insomnia, and increased infection risk.
• Immunosuppressants (Cyclophosphamide/Azathioprine/Mycophenolate): Reserved for severe renal involvement. Risks include bone marrow suppression, bladder toxicity (with cyclophosphamide), and secondary malignancies.
• Contraindications: NSAIDs should be used with extreme caution in patients with renal involvement, as they can exacerbate renal insufficiency.

7. Prognosis and Long-Term Management

The prognosis in adults is significantly worse than in children, primarily due to the risk of End-Stage Renal Disease (ESRD).

• Renal Monitoring: Adult patients with HSP require long-term follow-up of blood pressure and urinalysis (at least 2 years post-diagnosis).
• Factors Associated with Poor Prognosis:
  • Age > 50 at onset.
  • Persistent proteinuria > 1g/day.
  • Decreased GFR at presentation.
  • Severe histopathologic changes on renal biopsy (crescents in >50% of glomeruli).

8. Frequently Asked Questions (FAQ)

Q1: Is adult HSP considered a chronic or acute condition?
A: It is typically acute, but it can follow a relapsing-remitting course in about 20–30% of adult patients.

Q2: Can I get HSP more than once?
A: Yes, recurrent episodes are more common in adults than in children, often triggered by upper respiratory infections or medications.

Q3: When should I be worried about my kidneys?
A: Any presence of blood (hematuria) or protein in your urine after an HSP diagnosis requires nephrology consultation.

Q4: Is there a specific diet for HSP?
A: There is no specific diet, but maintaining hydration and avoiding nephrotoxic substances (including excessive NSAIDs) is critical.

Q5: What is the role of biopsy in diagnosis?
A: Biopsy is the gold standard for confirmation, especially when clinical features are atypical or when renal involvement is suspected.

Q6: Can HSP lead to permanent kidney damage?
A: Yes, approximately 10–20% of adults with HSP progress to significant renal impairment or ESRD.

Q7: Is HSP contagious?
A: No. While it is often triggered by an infection, the vasculitis itself is an autoimmune process and is not communicable.

Q8: Why is it called "Purpura" if it doesn't involve platelets?
A: The term refers to the clinical appearance (purple spots), which is caused by vessel wall inflammation (vasculitis), not low platelet counts.

Q9: Are steroids always necessary?
A: Not for mild (skin-only) cases, but they are generally required for patients with gastrointestinal or renal involvement.

Q10: What is the biggest danger with adult HSP?
A: The most significant long-term danger is silent, progressive renal failure, which is why consistent, long-term monitoring is non-negotiable.

9. Clinical Summary Table

Disclaimer: This guide is intended for educational and informational purposes for healthcare professionals. It does not replace clinical judgment or institutional protocols. Always consult current clinical guidelines (such as ACR or EULAR) when managing complex vasculitic cases.